New targets and challenges in the molecular therapeutics of cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Significant advancements in understanding cancer molecular changes over the past two decades.
• Identification of numerous molecular targets for novel therapeutic development.
• Approval of several targeted drugs and ongoing preclinical evaluations.

Purpose of the Study:

• To highlight the challenges in the preclinical and clinical development of targeted cancer therapies.
• To emphasize the need for patient stratification based on tumor molecular profiles.
• To address the complexities in determining effective biological doses for targeted agents.

Main Methods:

• Review of recent findings in cancer molecular biology and targeted drug development.
• Analysis of clinical trial designs and endpoints for targeted therapies.
• Discussion of off-target effects and patient response variability.

Main Results:

• Targeted therapies demonstrate significant activity but are often effective only in specific cancer subpopulations.
• Off-target drug effects can lead to toxicity or antagonism.
• Determining the appropriate biological dose alongside maximum tolerable dose is crucial.

Conclusions:

• Patient stratification is critical for optimizing targeted cancer therapy outcomes.
• Effective clinical trial designs must incorporate assays for biological dose determination.
• Addressing challenges in targeted drug development is essential for improving cancer treatment.